We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00852813
First Posted: February 27, 2009
Last Update Posted: February 27, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Katholieke Universiteit Leuven
  Purpose
The purpose of the study is to evaluate the tolerance of a higher dose of arabinoxylan-oligosaccharides (AXOS) and their prebiotic activity in healthy subjects.

Condition Intervention Phase
Healthy Dietary Supplement: arabinoxylan-oligosaccharides (AXOS) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects: a Randomized, Placebo-Controlled Cross-Over Study

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 20
Study Start Date: October 2007
Study Completion Date: June 2008
Intervention Details:
    Dietary Supplement: arabinoxylan-oligosaccharides (AXOS)
    intake period: 3 weeks, 10 g/day
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00852813


Locations
Belgium
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Publications:
Responsible Party: Kristin verbeke, Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier: NCT00852813     History of Changes
Other Study ID Numbers: AXOS 002
First Submitted: February 26, 2009
First Posted: February 27, 2009
Last Update Posted: February 27, 2009
Last Verified: February 2009

Keywords provided by Katholieke Universiteit Leuven:
tolerance
prebiotic
gastrointestinal effects